19:05 , Nov 30, 2018 |  BC Week In Review  |  Clinical News

Fauci details goals of new Ebola trial

The first randomized, controlled trial of potential Ebola therapies conducted during an outbreak has started enrolling patients in the Democratic Republic of Congo. The trial is intended to treat patients who are affected by an...
15:30 , Jun 8, 2018 |  BC Week In Review  |  Company News

DRC approves compassionate use of investigational Ebola treatments

A Democratic Republic of the Congo ethics committee approved the use of five investigational Ebola therapies under compassionate use and expanded access. The World Health Organization said four of the five approved products are in...
21:03 , Jun 6, 2018 |  BC Extra  |  Company News

DRC approves investigational Ebola treatments

A Democratic Republic of the Congo ethics committee approved the use of five investigational Ebola therapies under compassionate use and expanded access. The World Health Organization said four of the five approved products are in...
23:43 , May 31, 2018 |  BC Extra  |  Company News

Regeneron sends experimental Ebola therapy to Congo

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said it began shipping its investigational Ebola antibody cocktail REGN-EB3 (REGN3470-3471-3479) to the Democratic Republic of the Congo (DRC). REGN-EB3 was one of several experimental therapies considered for the treatment of...
18:23 , May 25, 2018 |  BC Week In Review  |  Company News

WHO to start treatment with Merck's Ebola vaccine

The World Health Organization began administering Ebola vaccine rVSV-ZEBOV (V920) from Merck & Co. Inc. (NYSE:MRK) on May 21 in two cities in the Democratic Republic of the Congo (DRC). Vaccination will be administered using...
23:03 , May 18, 2018 |  BC Extra  |  Politics & Policy

WHO: Congo may approve mAb Zmapp for Ebola outbreak

The Democratic Republic of the Congo is likely to approve the use of Zmapp “in the coming days” to treat patients affected by the country's Ebola outbreak, the World Health Organization said Friday. President Larry...
21:54 , Dec 1, 2017 |  BC Week In Review  |  Company News

BARDA awards $170.2M for Ebola vaccines

HHS’s Biomedical Advanced Research and Development Authority (BARDA) awarded four contracts totalling $170.2 million to fund late-stage development and purchase of Ebola vaccines. Merck & Co. Inc. (NYSE:MRK) will receive $39.2 million to develop its...
12:56 , Mar 15, 2017 |  BC Innovations  |  Distillery Techniques

Assays and screens

TECHNOLOGY: Diagnostic assays A plasmonic chip-based microarray could help aid the differential diagnosis of Zika and dengue infections. The assay utilized a gold plasmonic chip-based microarray printed with Zika virus genome polyprotein (GP1) and dengue...
07:00 , Oct 24, 2016 |  BC Week In Review  |  Clinical News

ZMapp: Additional Phase I/II data

Additional data from the open-label, international Phase I/II PREVAIL II trial in 71 patients with Ebola virus infection showed that 50 mg/kg IV ZMapp every 3 days plus standard of care (SOC) led to 28-day...
07:00 , Jun 2, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Ebolavirus glycoprotein; Niemann-Pick disease type C1 (NPC1)

Infectious disease INDICATION: Ebola Mouse and guinea pig studies identified a mAb that could help treat Ebola caused by the Ebola and Sudan species of Ebolavirus. A previously identified macaque-derived mAb bound Ebolavirus glycoprotein from...